Boxer Capital Management’s Contineum Therapeutics CTNM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$6.63M Hold
494,000
– – 0.58% 25
2026
Q2
$8.1M Hold
494,000
– – 0.61% 32
2026
Q1
$6.45M Hold
494,000
– – 0.85% 30
2025
Q4
$5.65M Buy
+494,000
New +$5.64M 1.24% 24

Other funds holding CTNM

Boxer Capital Management's CTNM Position: Q3 2026 in Review

Boxer Capital Management held its Contineum Therapeutics (CTNM) position steady in Q3 2026 at 494,000 shares worth $6.63M. The position accounts for 0.58% of the portfolio, ranked #25.

Boxer Capital Management first reported a position in CTNM in Q4 2025 and has held it in 4 quarters since. The position peaked at $8.1M in Q2 2026. 118 funds tracked by Wall St. Rank hold CTNM as of Q3 2026.

  • Boxer Capital Management held 494,000 shares of Contineum Therapeutics worth $6.63M as of Q3 2026.
  • Boxer Capital Management left its Contineum Therapeutics share count unchanged in Q3 2026.
  • Contineum Therapeutics made up 0.58% of Boxer Capital Management's portfolio in Q3 2026, its #25 holding.
  • Boxer Capital Management first reported a position in Contineum Therapeutics in Q4 2025 and has held it in 4 quarters since.
  • Boxer Capital Management's Contineum Therapeutics position peaked at $8.1M in Q2 2026.
  • 118 funds tracked by Wall St. Rank held Contineum Therapeutics as of Q3 2026.

Based on Boxer Capital Management's 13F filing for Q3 2026, filed 16 Nov 2026.